Get started

Biotech

Biomerica’s Covid-19 Antigen Rapid Test Receives CE MarkBiomerica’s Fast 15-Minute Simple to Use Covid-19 Antigen Rapid Test Receives CE Mark Biomerica receives first orders and plans to ship tests in coming weeks Clinical studies demonstrated an overall performance of 94.7% positive agreement (sensitivity) and 99.7% negative agreement (specificity) as compared to lab-based molecular PCR tests The Company has already received its first European orders and plans to ship the first part of these orders in the coming weeks. The Company will now begin marketing this product broadly in Europe and other regions outside of the US. merica’s new COVID-19 Antigen Rapid Test is highly portable, affordable, and provides results in 15 minutes with no equipment required to perform or read the test. finance.yahoo.com
NASDAQ:BMRA
by AlenCiken
BIOLASE Announces Agreement With DSO Dental Care AllianceBIOLASE Announces Agreement With DSO Dental Care Alliance To Expand Laser Adoption In Dental Offices Across The United States BIOL announced an agreement with Dental Care Alliance (DCA), one of the largest dental support organizations (DSO) in the United States with more than 330 affiliated practices in 20 states, to expand laser adoption and hands-on training programs in targeted geographies. The Company expects the agreement to lead to a rollout across all DCA offices in 2021. finance.yahoo.com
B
by AlenCiken
1
This NCNA Penny Stock Could Surge Over 300%, Say AnalystThis NCNA Penny Stock Could Surge Over 300%, Say Analyst NuCana uses a phosphoramidate chemistry technology called ProTide to create a class of drugs that will surmount the limitations of the existing nucleotide analogs behind many chemotherapy drugs. NuCana’s ProTides have already been used in Gilead’s antiviral drug Sovaldi. In May of last year, NuCana announced the restart of its Phase III trial on Acelarin, the drug candidate furthest along the company’s pipeline, as a treatment for biliary tract cancers. The study encompasses over 800 patients in 6 countries and is currently ongoing. In November, the company published data described as ‘encouraging’ from the Phase Ib study of the same drug. While Acelarin is the flagship drug in the pipeline, NuCana has two other prospects under development. NUC-3373 is in Phase I trial as a treatment for solid tumors and colorectal cancers, and NUC-7738 is a second pathway under investigation for applications to advanced solid tumors. Of these three, the colorectal study is the farthest advanced. 5-star analyst Robyn Karnauskas sees the pipeline as key to NuCana’s investor potential. “We believe investors have overlooked the fact that NCNA is a platform Company that we believe is validated, as defined by the production of clinical products. We like that it has brought 3 products to the clinic, including one novel drug and two improved cornerstone chemos. The data suggest to us that the platform works and can produce better chemos While investors are mostly focused on Acelarin, we believe investors should also focus on NUC-3373, another core to our platform-based thesis that has data expected in 1H2021,” Karnauskas noted. To this end, Karnauskas puts a $22 price target on NCNA, suggesting the stock has room for 384% growth ahead of it, along with a Buy rating. finance.yahoo.com
NASDAQ:NCNA
by AlenCiken
5
This ACRX Penny Stock Could Surge Over 300%, Say AnalystsThis ACRX Penny Stock Could Surge Over 300%, Say Analysts AcelRx is a pharmaceutical company dedicated to the creation of safer treatments for acute pain, developing synthetic opioid drugs for sublingual (under the tongue) dosing. The company’s main product, Sufentanil, was approved by the FDA under the name Dsuvia in 2018, and by the EU as Dzuveo that same year. A second sublingual Sufentanil system, under the name Zalviso, has also been approved for use by the EU, and is in Phase 3 trial in the US. In its most recent earning report, the company showed $1.4 million at the top line, driven by $1.3 million in product sales. The sales figure was up 433% sequentially, and the total revenue figure was up 133% year-over-year. Cantor analyst Brandon Folkes is upbeat on Dsuvia’s prospects as an alternative to current opioid treatments, and he believes that potential will boost the company’s stock. As ACRX launches a true alternative to IV opioids, we expect investors to begin to appreciate the value of the product. In line with his bullish stance, Folkes rates ACRX a Buy, and his $9 price target implies room for a stunning 552% upside potential in the next 12 months. finance.yahoo.com
A
by AlenCiken
T2SARS-CoV-2™ Panel can detect multiple variants of the SARS-CoVT2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S. T2SARS-CoV-2 Panel, which has demonstrated clinical sensitivity of 95 percent and specificity of 100 percent. The T2SARS-CoV-2 Panel provides results in under two hours utilizing an upper respiratory swab sample. The test runs on the Company’s FDA-cleared and fully-automated T2Dx® Instrument, which is capable of performing seven tests simultaneously and up to sixty samples per day. finance.yahoo.com
NASDAQ:TTOO
by AlenCiken
Exclusive Licensing Agreement for GIAPREZA and XERAVA in EuropeLa Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments Under the terms of the exclusive licensing agreement, La Jolla will be entitled to receive: (i) an upfront cash payment of $22.5 million; (ii) potential commercial milestone payments of up to $109.5 million; and (iii) double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories. finance.yahoo.com
L
by AlenCiken
Stock to watch: Veru Inc (NASDAQ: VERU)NASDAQ:VERU An interesting stock to watch. The asset is in a 1,5 month uptrend without major pullbacks + MACD Crossover indicator's Long signal is still in progress. The buy zone is marked out, targets are 12.5, 15, 18, 23,88 and towards the all-time high. Invalidation: closing below the gap. Disclaimer: This article should not be considered as financial or investment advice. Trading digital assets involve risk and may resolve in the loss of your capital. Always be sure to understand the amount of risk involved and do your research before taking any trading/investment steps.
NASDAQ:VERULong
by randomname11
Day Traders Lighting Up Reddit Spur Rally in ZomedicaDay Traders Lighting Up Reddit Spur Rally in Tiny Health Stock Zomedica Such outsized moves in small-caps are becoming par for the course these days. Surging at the open on the back of mentions in Reddit forums was Zomedica Corp., a company that develops medicines for pets. The stock jumped as much as 98% on Monday and is up almost four-fold from the start or the year. The penny stock garnered a mention in several Reddit forums over the past few days finance.yahoo.com
AMEX:ZOM
by AlenCiken
2
Day Traders Lighting Up Reddit Spur Rally in TransEnterixDay Traders Lighting Up Reddit Spur Rally in Tiny Health Stock TRXC The stock has surged about 180% since the start of the new year. Today’s trading volume was more than 13 times normal. The penny stock garnered a mention in several Reddit forums over the past few days, with one user comparing it with the roughly $95 billion market-cap leader in surgical robotics, Intuitive Surgical Inc. TransEnterix markets the Senhance surgical system, cleared by the U.S. Food and Drug Administration in 2017. According to the device-maker in an update last week, 10 of the systems were installed in 2020. The Morrisville, North Carolina-based company said it ended 2020 with $17.5 million in cash and equivalents, enough to keep the company afloat into the third quarter. finance.yahoo.com
T
by AlenCiken
3
GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine DevelopmentGeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The Phase 1 grant, titled, “Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19,” will support the ongoing design, construction and preclinical testing of GeoVax’s vaccine candidates in preparation for human clinical trials. The efficacy testing will be performed in collaboration with the University of Texas Medical Branch (UTMB). Vaccines using the GV-MVA-VLP platform developed for other pathogens have proven to be efficacious with a single dose, having strong durability which would be a significant advantage for SARS-CoV-2 global vaccination campaigns.” We are pleased to receive this Phase 1 SBIR funding award, which will supplement the internal resources allocated to our COVID-19 vaccine program and accelerate our progress toward human clinical trials. finance.yahoo.com
NASDAQ:GOVX
by AlenCiken
Reduction in Heart Attacks, Strokes and Cardiac DeathSingle Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Patients With Chronic Heart Failure results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who received rexlemestrocel-L (REVASCOR®) or control sham. A single dose of rexlemestrocel-L resulted in substantial and durable reductions in heart attacks, strokes, and cardiac deaths. The incidence of heart attacks and strokes were reduced by 60% over a median follow-up period of 30 months following a single dose of rexlemestrocel-L in the population of 537 patients with New York Heart Association (NYHA) class II or III chronic heart failure (5% vs 13%, p=0.002). The incidence of death from cardiovascular causes was reduced by 60% following a single dose of rexlemestrocel-L in the 206 patients with NYHA class II disease (8% vs 20%, p=0.037) finance.yahoo.com
NASDAQ:MESO
by AlenCiken
1
HBIO Bull Case Breaking through the double top barrier, HBIO is now gathering support around the previous resistance level. The stock has been in a steady accumulation stage with a strong uptrend and increasing volume. The strong uptrend should continue. The Benchmark Company has also changed their status from a Speculative Buy to a Buy, as of today. There is enough volume to identify a cup and handle pattern. You can also identify a rising triangle from point X to the support level forming line 1, and point B up to the current low price making up line 2. This is a continuation pattern, indicating the direction of the price movement should continue, which in the current stage is up. All these patterns indicate that HBIO is likely to have a bull run. The price target is $6, a 36% upside from the current price of 4.4
NASDAQ:HBIO
by ayushranjanth
ISR has received FDA 510(k) clearanceC4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer ISR has received FDA 510(k) clearance for the use of C4 Imaging’s Sirius® positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Sirius MRI Markers will enable Isoray’s customers to fully utilize the benefits of MRI seed localization. Brachytherapy, or internal radiation therapy, is a leading, cost-effective option for the treatment of prostate cancer. Isoray is the world’s only producer of Cesium-131, commercially known as Cesium Blu™, brachytherapy seeds. Cesium-131 is a radioactive isotope that delivers a minimally invasive and highly targeted treatment to the site of the cancer preserving healthy tissue and organs. Patients benefit from the rapid resolution of their side effects allowing them to return to their normal lives quickly. finance.yahoo.com
I
by AlenCiken
2
“Strong Buy” Penny Stock That Could Deliver Massive Returnis engaged in the development of gene therapies for rare, frequently terminal, diseases, including neurometabolic disorders, primary immune deficiencies, and blood disorders. The gene therapy approach uses blood stem cells to deliver corrected genetic information directly into the patient’s body. Orchard’s pipeline demonstrates the diversity of disorders amenable to gene therapy – the company has no less than 12 drug candidates in development. Among these candidates, Libmeldy (OTL-200) stands out. Libmeldy is in commercialization stages as a treatment for MLD (metachromatic leukodystrophy), a rare, mutation-based genetic disorder of the nervous system, received its approval for medical use in the EU in December 2020. “We look forward to the company’s commercial execution in the EU and an eventual 2022 approval in the US. Last month ORTX received IND clearance from the FDA for the program paving the way for discussions with the US regulators to decide a suitable path forward toward a BLA filing.” with possibly two gene therapies approved in the next 12-18 months and a pivotal study beginning in a third (MPS-I), we think ORTX shares are undervalued at these levels," the analyst concluded. Wedbush analyst David Nierengarten rates ORTX as Outperform (i.e. Buy), and his $15 price target indicates a potential for 241% growth in the year ahead. Only Buy ratings, 3, in fact, have been issued in the last three months. Therefore, ORTX gets a Strong Buy consensus rating. At $15, the average price target indicates shares could appreciate by 241% in the year ahead. finance.yahoo.com
O
by AlenCiken
“Strong Buy” Penny Stock That Could Deliver Massive Returns“Strong Buy” Penny Stock That Could Deliver Massive Returns The company’s development pipeline features drug candidates under investigation as treatments for short bowel syndrome (SBS) and celiac disease (CeD), two conditions that are both dangerous and difficult to treat. 9 Meters’ flagship product, Larazotide, is in Phase 3 development for the treatment of CeD. CeD affects about 1% of the population, yet there are no approved therapies. Top-line data from the study is expected in the second half of 2021. this past December, the company announced that it had entered an agreement with EBRIS, the European Biomedical Research Institute of Salerno, to investigate Larazotide as a potential treatment for respiratory complications due to COVID-19. The other major drug in the company’s pipeline is NM-002, for SBS. The company has recently announced positive Phase 1b/2a results, with a measurable impact on disease symptoms from a compound that was well-tolerated by patients. finance.yahoo.com
N
by AlenCiken
positive prelim data from a Phase 1 study-leukemia treatmentCuris Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes. Key findings include: - Marrow blast reductions observed in all evaluable patients (6 patients). - 6 of 7 patients enrolled remain on study. - Patients enrolled experienced a median of 3 prior lines of treatment (range 1-4). - Two patients experienced a marrow complete response, one with blast count going from 23% pretreatment to 1% on treatment, and the other going from 11% pretreatment to 2% on treatment. - No DLTs observed in 7 DLT-evaluable patients in the 200 mg BID and 300 mg BID cohorts. - Enrollment has begun in the 400 mg BID cohort. Curis said its CA-4948 monotherapy in adult patients was well tolerated, has demonstrated signs of biologic activity in the ongoing study and is capable of achieving "relevant levels of drug exposure." finance.yahoo.com
NASDAQ:CRIS
by AlenCiken
I have a strong feeling... (EDSA)Hello everybody and happy new year! ❤ Major retest of breaking 6-7 years of channel Resistance. The retest after a very strong impulsive move out of the channel is forming a falling wedge with very tight price consolidation. Another plus about this stock is that it has a very low float. I like accumulation here, maybe one more chance at 3.56 I'm extremely bullish on this and see a lot of correlation with a lot of other low float biotech / pharmaceutical stocks. My thoughts on a very long term swing trade, See you at the top 🚀
NASDAQ:EDSALong
by UnknownUnicorn2319099
6
Huge upside potentialContraceptives (just like vitamins and/or other medicine and supplements) are and always be crucial, no matter what is the economic situation. This is why I'm looking at and showing you TXMD. TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. We develop products to address the unique changes and challenges women experience throughout the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. Check out their website if interested in more info, I just quoted this above from there. Lately (but before the 2020 crash) this stock was in the range between $5 - $7 (much higher before) and you could make a 30-40% profit on a swing trade. But now the good side of this Covid situation and the fact that everyone was buying EV, stay at home, tech and similar popular stocks so far, is that some of the other market participants like biotech, REIT or energy didn't go so well. But now it's time for this one to regenerate too. By "now" I mean within a year or so. Realistically I see this should get to that range again, between $5 and $7 and consolidate around it, but of course it can take several brakes (profit taking) on the way up, at those levels I marked. Also it can go any higher to the $10 area or even more, we can not tell yet for sure. But right now it is way under valued and beaten down, so it is a strong buy in my opinion. And here is my "story" again: Probably I’ll post this text several times (under each ticker) that I mention below, as the meaning of the writing necessitate it. Introduction and the mindset: 8-10% of my wealth is in the US stock market, other almost 90% in real estate in Europe. As for the stocks, you got to have a diversified portfolio in my opinion. As my experience tells me you can be lucky sometimes and you also gonna be unlucky at any given time (and it’s unexpected all the time). So one can not count on luck and/or feelings (I call it being on Hope-ium). This is the reason for the need of diversification, especially in this unprecedented (word of 2020, right?) environment. Lots of analysts say the market is overvalued, stock prices are overstretched (the SPY and tech at least). I think this is partially true and it does matter sometimes, it does not matter too much other times and/or instances as you’ll see soon below. OK, too much talk already, I will show you my portfolio and talk about my ideas with numbers, entry points, targets and even risks. My past fundamental ideas (as for reputation, not a bluffer): In 2019 I only had 2 ideas, both based on my fundamental analysis and they were for investment (so, not for short term trade ideas). Tesla and Bitcoin. For TSLA my entry plan and buying advice was @ $426 in December (pre-split price, so if you are new, divide it by 5). For BTC I stated that I recon we have to wait for the beginning of 2020 (according to my plan it was most likely for about February) and buy the expected dip - according to my readings - at $5500. Of course Covid came and things got crazy, but we didn’t expect that. Lots of losses and learning, but here I share some useful thoughts and ideas. I learned technical analysis, but these fundamental ideas born according to my own research, also I didn’t know any known influencer back then. My recent/actual ideas and how to do it: I divide my stock portfolio for 5 sectors in a way that if even 3 or 4 of them fails, the other 1 or 2 will pay out so much, I wouldn’t mind and never lose. My sectors watched: 1.REIT (they will recover and pay good dividends) 2.Energy (they will recover as soon as Covid is over) 3.Commodities (we need them whatever happens) 4.Biotech (necessity too, no matter what) 5.Insurance (self explanatory). The SPY is driven by tech, so I left it out for now (with a small exception), as no need to risk now, because tech is a bit overstretched at the moment and even if it’s going way higher, my ideas will too. But if tech is not going higher, I will still make profits (hence the so called ‘K-shape recovery’). Not easy to do this in such overvalued levels but not everything is expensive and also note, that not every cheap stock is going to die off, so the main buying habit of mine is what George Gammon likes also: “I buy a dollar for fifty cents” if I may quote him here. This idea means that I buy according to the actual (and my own) valuation, plus the current stock price of the company and not according to the momentum or the horde, in other words the ‘best performers’ according to popular Youtubers, similar influencers (or the mainstream media for that matter), as history shows that the majority loses and the minority wins (at least during those crazy unprecedented times like now when soon everyone is in the stock market. The examples I analyzed: 1929, 2000, 2008). Doesn’t the 2008 example tell you that it would be wiser to be on the side of Michael Burry during the stock market rally instead of everyone else? Yeah, I know, it’s not easy and also, “this time will be different” :D But jokes aside, I believe at least in a way this time it actually could be different, the task is to understand fundamentals, think a lot and make smart decisions based on your own research. And the more you read and think, the closer you might get to some advantage and solution that will pay off highly likely in every possible scenario in the future. Why and how? A simple enough hint of mine for example is, if a stock is a ‘top performer’ that fact might actually mean it already did what we expected from it to do (otherwise why the term?), so you kind of could already be late, but you would never know. This is when FOMO comes in to play, beware! Sure, you can be lucky and participate in a bubble just like how it was with Yahoo in 1999-2000 but only afterwards (years later) could you for sure realize that it wasn’t a good idea to buy in around 1999 as you didn’t sell at the top (2nd of January, 2000) did you? Even though the “long term fundamentals” that they talked about back then, they all turned out to be 100% true, because tech went higher for sure, Apple is still a winning company, we are surrounded with computers, smartphones and it's all tech and internet and websites, we still use yahoo mail every day and listen to yahoo finance and so on. Tech is cool and king. Still, the dot com bubble was bad and painful for the majority. See, everyone was right except for the ones who bought in at the high prices because of FOMO and/or the ones who didn’t sell at the top, and I think this applies to the majority. As you see now, those ‘top performers’ worked very well for those who bought in at the bottom or even half way to the top for swing trades (but that was just before you heard about them and not really any time later). So, the problem is that no one ever knows when is the top of a bubble or of any kind of run up that is driven by sentiment if it’s not a slow and steady growth corresponding both the fundamentals and financials in other words the real growth of a company. So the solution is to better find one that is trusted and/or have future and not going bankrupt soon and is beaten down to the ground. That’s when you buy in. Warren teaches this too, but this is my own thinking and just a coincidence that the old man says it too. So, I reveal here all my stocks and investment picks that I either bought and/or had planned or advised to buy so far with my first entry prices during 2020 (not placed in order of any sort, but just random). The majority are investments for 3-5 years the exceptions are the swing trades: TSLA again @ $358 (pre split); NYMT @ $1; IVR anywhere below $4; NIO anywhere below $5 (swing trade); HEXO @ $0.74 (pre split); ASTC @ $1.82 (swing trade); CDEV @ $1; LMND @ $47; TXMD @ $1.2; LXRX @ 1.93; GNW @ $3.26 (swing trade); WPG @ $1 (pre split); CRSP @ $60; gold below $1700; AAL @ $10 (swing trade); AMC @ $2.84 (swing trade); BTC @ $5500 for investment (and was swing trade too, from $7000 to $9000 because I had to pay property tax and did it from the profit).
NASDAQ:TXMDLong
by janfoux
2
Random Pick of The Week | $AKBA BioTechWelcome to the first "Random Pick of The Week", where I will randomly select a ticker to chart based on comments posted below or sent via direct message. Want a technical breakdown? - Follow Me - Smash Like - Comment 1 Ticker Todays's Pick: AKBA / Akebia Therapeutics Inc. Looking at the great scheme of things, we can see that AKBA has been in a steady downtrend for the last 5 years with only a few points of high demand. We've seen some massive leaps throughout the last 5 years, which is as expected knowing that we are trading biotech. We look like we will sit in a wedge up toward the start of 2021, leaving us with sideways movement (-+8%) until. We look for a breakout and retest of this wedge if bulls have any hope of any run into the New Years'. If we break out, we have $3.95 set as a short-term target and $7 as our long-term. We must watch $2.75/$2.70 as our weekly support, if lost look to short toward $2.10/.20. FYI: Ignore the green box, it decided to change angles last second. DCJ | Happy Holidays
NASDAQ:AKBALong
by DotcomJack